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Aurora kinases are essential for cell division and are frequently misregulated in human 
cancers. Based on their potential as cancer therapeutics, a plethora of small molecule 
Aurora kinase inhibitors have been developed, with a subset having been adopted as 
tools in cell biology. Here, we fill a gap in the characterization of Aurora kinase inhib-
itors by using biochemical and cell-based assays to systematically profile a panel of 
10 commercially available compounds with reported selectivity for Aurora A (MLN8054, 
MLN8237, MK-5108, MK-8745, Genentech Aurora Inhibitor 1), Aurora B (Hesperadin, 
ZM447439, AZD1152-HQPA, GSK1070916), or Aurora A/B (VX-680). We quantify the 
in vitro effect of each inhibitor on the activity of Aurora A alone, as well as Aurora A and 
Aurora B bound to fragments of their activators, TPX2 and INCENP, respectively. We 
also report kinome profiling results for a subset of these compounds to highlight potential 
off-target effects. In a cellular context, we demonstrate that immunofluorescence-based 
detection of LATS2 and histone H3 phospho-epitopes provides a facile and reliable
means to assess potency and specificity of Aurora A versus Aurora B inhibition, and 
that G2 duration measured in a live imaging assay is a specific readout of Aurora A 
activity. Our analysis also highlights variation between HeLa, U2OS, and hTERT-RPE1 
cells that impacts selective Aurora A inhibition. For Aurora B, all four tested compounds 
exhibit excellent selectivity and do not significantly inhibit Aurora A at effective doses. For 
Aurora A, MK-5108 and MK-8745 are significantly more selective than the commonly 
used inhibitors MLN8054 and MLN8237. A crystal structure of an Aurora A/MK-5108 
complex that we determined suggests the chemical basis for this higher specificity.
Taken together, our quantitative biochemical and cell-based analyses indicate that
AZD1152-HQPA and MK-8745 are the best current tools for selectively inhibiting Aurora 
B and Aurora A, respectively. However, MK-8745 is not nearly as ideal as AZD1152-
HQPA in that it requires high concentrations to achieve full inhibition in a cellular context, 
indicating a need for more potent Aurora A-selective inhibitors. We conclude with a set 
of “good practice” guidelines for the use of Aurora inhibitors in cell biology experiments.
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inTrODUcTiOn
Aurora kinases were discovered in the mid-nineties in Drosophila 
and yeast (1, 2). Whereas yeasts only have one Aurora kinase, 
metazoans generally have two, named Aurora A and B. Mammals, 
but not other vertebrates, also have a third family member, Aurora 
C. Aurora A localizes to centrosomes and spindle microtubules 
and plays important roles in centrosome maturation, control-
ling spindle length and bipolarity, asymmetric cell division, and 
promoting mitotic entry both in unperturbed cells and following 
DNA damage (3, 4). Aurora B localizes to chromosomes/inner 
centromeres and the spindle midzone and is implicated in many 
processes including chromosome condensation, chromosome 
biorientation on the spindle, and cytokinesis (5–7). Aurora C is 
expressed in testis (8), where it exhibits tissue-specific functions 
(9, 10), and in oocytes, where it contributes to early embryonic 
divisions by providing functions associated with Aurora B 
in somatic cells (11–14). In addition, Aurora C is aberrantly 
expressed in cancer cells (15).
Due to their closely related kinase domains (72% identity for 
the human proteins), Aurora A and B exhibit similar protein 
substrate preferences in vitro (16–19). In vivo, their distinct sub-
strate specificities, localization patterns, and functions arise from 
interactions with specialized binding partners (3, 4). Aurora B is 
largely found as part of the four-subunit chromosomal passenger 
complex (CPC) (5–7) whose three other members  –  INCENP, 
survivin, and borealin – localize the kinase to the centromere and 
the anaphase spindle. INCENP also activates Aurora B via a two-
step mechanism (20–22). The IN box at the INCENP C-terminus 
first wraps around the N-terminal lobe of Aurora B, stimulating 
autophosphorylation of the activation loop residue Thr 232 (23). 
This event allows Aurora B to phosphorylate serines in the TSS 
motif adjacent to the IN box, which generates a feedforward loop 
by further augmenting INCENP’s ability to bind and activate 
Aurora B.
Aurora A has multiple regulators, with the best-studied one 
being TPX2, which activates the kinase and targets it to spindle 
microtubules (24–26). Structural studies have shown that the 
TPX2 N-terminus binds the N-terminal lobe of Aurora A, in a 
manner distinct from how the INCENP IN box binds Aurora B, 
facilitating the alignment of residues essential for substrate bind-
ing and catalysis (27–29). In biochemical assays, binding of the 
TPX2 N-terminus increases autophosphorylation of the activa-
tion loop residue Thr 288 (28, 30, 31). As in the case of Aurora B, 
phosphorylation of this threonine [which readily occurs in vitro 
even in the absence of TPX2 or other activators (16)] promotes 
high levels of kinase activity (16, 28, 32). However, recent studies 
have unexpectedly revealed that this autophosphorylation event 
is not essential for TPX2 stimulation of Aurora A kinase activity; 
fully dephosphorylated Aurora A bound to TPX2 exhibits robust 
enzymatic activity (28, 32). The relative contributions of TPX2 
binding and Thr 288 phosphorylation to different cellular Aurora 
A functions is an active area of investigation.
Coincident with the delineation of their cellular roles, the 
Aurora kinases were also found to be amplified/overexpressed 
in cancer (33, 34). Functional studies of Aurora A revealed a 
potential role in tumor initiation and growth – increased expres-
sion of Aurora A transformed rodent fibroblasts (albeit weakly) 
and promoted their ability to form tumors in  vivo (35, 36). In 
addition, elevated Aurora A activity was shown to confer resist-
ance to taxol-mediated apoptosis in cancer cells (37). The Aurora 
kinases therefore emerged as attractive drug targets in cancer and 
became the focus of intense drug discovery efforts (38–41).
At least 30 Aurora kinase inhibitors have been evaluated 
preclinically or clinically as potential oncology therapeutics 
(38). The development of these inhibitors has typically involved 
high throughput biochemical assays using purified proteins, 
structure-based drug design, cellular biomarker assays (primar-
ily Aurora A Thr 288 phosphorylation and Aurora B-mediated 
phosphorylation of its canonical substrate, histone H3), cellular 
proliferation/cytotoxicity assays, and xenograft models in mice 
(39). The products of the vast majority of these programs have 
been compounds that potently inhibit all three Aurora kinases 
(A, B and C), as best exemplified by the first clinically tested 
Aurora kinase inhibitor, the Vertex/Merck pyrazolo-pyrimidine 
compound VX-680 (MK-0457, tozasertib; Figure  1) (42, 43). 
However, compounds that exhibit preference for Aurora A or 
B/C have also been developed. In 2003, two pioneering academic-
industrial collaborations described two distinct Aurora B inhibi-
tors: the indolinone Hesperadin and the quinazoline ZM447439 
[Figure 1; (44, 45)]. The latter compound was further optimized to 
produce the structurally related pro-drug AZD1152 (barasertib); 
barasertib is metabolized to the active form AZD1152-HQPA, 
which lacks the phosphate group present on AZD1152 and is 
the form typically used in biochemical and cell-based studies 
(Figure 1) (46, 47). In 2007, Millenium (now Takeda) described 
the first Aurora A-selective inhibitor, the benzazepine MLN8054 
(48–51), which, due to central nervous system side effects (52, 
53), was replaced as the lead clinical candidate by the derivative 
MLN8237 (alisertib; Figure 1) (49, 54, 55). In parallel, optimiza-
tion of the VX-680 scaffold by Merck/Banyu/Vertex resulted in 
the Aurora A-selective inhibitors MK-5108 (VX-689) (56) and 
MK-8745 (57, 58) (Figure  1). More recently, other structur-
ally unrelated Aurora A- and B-selective inhibitors have been 
described, such as the bisanilinopyrimidine inhibitor Genentech 
Aurora Inhibitor 1 (optimized to target Aurora A) (59) and the 
azaindole-based GSK1070916 (optimized to target Aurora B/C) 
(60–62) (Figure 1).
While these compounds were developed with a primary 
emphasis on therapeutic benefit, they were rapidly adopted by 
academic investigators as chemical tools for biochemical, struc-
tural, and cell biological studies (63). Application of these small 
molecules has complemented genetic knockdown and immu-
nodepletion approaches because their inhibitory effects exhibit 
high penetrance/rapid onset and can be readily reversed. Their 
use has been wide ranging and influential, resulting in a large 
body of work defining Aurora kinase cellular functions, identify-
ing potential substrates, and elucidating molecular mechanisms 
of kinase activation (63).
Despite the common use of several Aurora inhibitors by the 
cell biology community, a systematic comparison of these com-
pounds in quantitative in vitro and cellular assays has been lacking. 
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FigUre 1 | chemical structures of aurora kinase inhibitors analyzed in this study. The chemical structures of the 10 commercially available compounds 
characterized in this study are depicted (see Table S1 in Supplementary Material for suppliers). Outlined boxes group chemically related inhibitors: Pyrazolo-
pyrimidine class (Vertex/Merck/Banyu) – MK-5108 and MK-8745 were derived from VX-680 (orange outlined box); Benzazepine class (Millenium/Takeda) – MLN8237 
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Further, it is presently unclear how the potencies, selectivities, 
off-target profiles, and cellular efficacies of the most frequently 
used inhibitors compare to those of more recently described, 
potentially improved molecules. Here, we fill this gap by profiling 
the 10 commercially available inhibitors shown in Figure  1 in 
biochemical and cell-based assays. Our results highlight signifi-
cant challenges in the selective inhibition of Aurora A, identify 
the best compounds for specific and potent targeting of Aurora 
A and Aurora B, and lead us to present a set of recommendations 
for the experimental use of these compounds.
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resUlTs
Quantitative Biochemical analysis of 
inhibitor Potency and specificity
We began by analyzing the inhibitory properties of the 10 com-
pounds in Figure 1 (see Table S1 in Supplementary Material for 
suppliers) on the in vitro activities of full-length human Aurora 
A, alone or bound to an activating N-terminal peptide fragment 
of TPX2 (residues 1–43), and full-length human Aurora B bound 
to a C-terminal fragment of INCENP (residues 783–918, which 
includes both the IN box and TSS motifs; Figure  2A). As the 
large number of required measurements (3–11 independent sets 
of triplicate 12–36 point dose–response curves per compound) 
precluded the use of conventional radiometric substrate phos-
phorylation assays, we explored several recently developed high 
throughput methods for measuring kinase catalytic activity in 
multi-well microplate format (64). To allow comparison of Aurora 
A and B activity under similar reaction conditions (Figure 2A), 
we ultimately selected a sensitive assay format that monitors ADP 
production (ADP-GloTM – see Materials and Methods). Briefly, 
kinase reactions (with or without inhibitors) were performed 
in 384-well plates with saturating amounts of a generic peptide 
substrate containing the Aurora kinase consensus phospho-
rylation motif (Kemptide – LRRASLG; Aurora kinase consensus 
RRXS/T). After a defined incubation period, an enzyme cocktail 
was added to terminate the reaction and convert any remaining 
ATP to cyclic AMP. This was followed by a second enzyme cocktail 
that converted the ADP produced by the kinase reaction to ATP 
and, in turn, the newly generated ATP to a luminescent signal via 
luciferase. The resulting luminescence was then quantified using 
a microplate reader (Figure 2A).
Given the high affinities of the inhibitors and the enzyme 
concentrations required for sufficient signal-to-noise, some 
experiments were performed under “tight binding” conditions 
(66). Under these conditions, the total active enzyme concentra-
tion ([E]t) matches or exceeds the dissociation constant for the 
enzyme/inhibitor complex (Ki); therefore, the assumption that 
the concentration of free inhibitor is equivalent to that added to 
the reaction is not valid. The Ki was therefore calculated from the 
measured IC50 (concentration for half maximal inhibition) using 
the equation shown in Figure 2B (66–69). Use of this equation 
assumes that the compounds act through a direct competitive 
mechanism and requires that the substrate concentration [S], 
which in this case is [ATP], Km(ATP), and [E]t be precisely known. 
Therefore, for all three enzyme species employed in this analysis, 
we first measured Km(ATP) through an ATP titration (Figure 2C), 
and then performed all reactions at [ATP] =  Km(ATP) so that 
the denominator simplified to two. We also measured [E]t using 
inhibitor titrations under conditions where [E]t and [I] >> Ki, 
which enables the approximation that IC50 ~ [E]t/2 (Figure 2C). 
Example dose–response curves for MK-8745, the measured 
IC50s, and the resulting Ki values are depicted in Figure 2D. Ki 
values for all 10 inhibitors for Aurora A, Aurora A/TPX21–43 and 
Aurora B/INCENP783–918 are reported in Table  1. The Ki values 
were used to calculate the selectivity ratios of each inhibitor for 
the three enzyme species (Table 2). Because of the extremely slow 
on-rate of GSK1070916 for Aurora B/INCENP, this Ki could not 
be accurately measured under our conditions, so the previously 
described value (61) was used for selectivity analysis. For refer-
ence, the published Aurora A/TPX21–43Ki for GSK1070916 is also 
presented in Table 1.
Consistent with previously reported measurements [Table S2 
in Supplementary Material; (42, 70)], the well-characterized pan-
Aurora inhibitor VX-680 inhibited both Aurora A and Aurora B/
INCENP783–918 with essentially identical potencies [(Ki=1.0 nM); 
Table 1]. This compound was therefore included as a reference in 
the assays for the remaining nine compounds. We note that, based 
on significant differences in enzyme construct design, sources, 
purification methods, as well as assay conditions/readouts, it is 
not straightforward to compare our Ki values to values in the 
literature (which are, in many cases, wide ranging). Therefore, for 
all compounds (beyond VX-680), we largely restrict our discus-
sion of prior work to trends in potency and selectivity ratios.
As expected, all of the compounds reported to be Aurora 
B-selective were extremely potent Aurora B/INCENP783–918 
inhibitors with a rank order of potency of AZD1152-
HQPA  >  Hesperadin  >>  GSK1070916 (61)  >  ZM447439 
(Table 1) and exhibited a high selectivity (minimum of 30-fold) 
for Aurora B/INCENP783–918 over Aurora A (Table 2). Although 
our mean Aurora B/INCENP783–918Ki value (0.02 nM) (Table 1) for 
AZD1152-HQPA is ~18-fold lower than that previously reported 
[0.36 nM; Table S2 in Supplementary Material; (46, 47)], this is 
also the case for the Aurora A Ki values [~16-fold; 84 nM in this 
study (Table  1) versus 1.4  µM from published work (Table S2 
in Supplementary Material; (46, 47))]. Thus, the selectivity ratio 
calculated from our measurements is similar to that which can 
be derived from prior work (3760-fold versus 3890-fold) (Table 2 
and Table S2 in Supplementary Material).
All of the described Aurora A-selective inhibitors had sub-
nanomolar Kis for Aurora A, with a rank order of potency of 
MK-5108 > MLN8237 > MK-8745 > MLN8054 > Genentech 
Aurora Inhibitor I (Table 1). MK-5108 exhibited an inhibition 
constant below what we could accurately measure (≤10 pM). 
All of these compounds inhibited Aurora B/INCENP783–918 less 
potently than Aurora A, with MK-8745 exhibiting the high-
est selectivity for Aurora A (1,030-fold) and MLN8054 and 
MLN8237 the lowest (11- and 27-fold, respectively) (Table 2). 
The selectivity measured for MLN8054 was lower than the pub-
lished value [Table S2 in Supplementary Material; 43-fold (48)], 
possibly in part because this previous calculation was based on 
IC50s, which can be highly dependent upon [ATP], Km(ATP), 
and potentially [E]t (Figure  2B). In agreement with this, the 
Ki-based selectivity ratio we report for MLN8054 (11-fold) 
(Table 2) is close to that described in a structural, biochemical, 
and mutational analysis of the Aurora A inhibitory properties 
of MLN8054 (6-fold) (71).
Given the importance of TPX2 as an Aurora A regulator, 
we also assessed the inhibitory activity of all 10 compounds on 
the Aurora A/TPX21–43 complex. Excluding Genentech Aurora 
Inhibitor I and Hesperadin, the presence of TPX21–43 weakened 
binding by 4- to 8.1-fold (Tables 1 and 2). Intriguingly, TPX21–43 
increased the affinity of Genentech Aurora Inhibitor I for Aurora 
A 2.5-fold, whereas Hesperadin binding was unaffected (Tables 1 
and 2). Decreased Aurora A Kis in the presence of TPX21–43 has 
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been previously reported for VX-680, MK-5108, MLN8054, and 
MLN8237 [Table S2 in Supplementary Material; (70–72)].
Binding of the TPX2 N-terminus to Aurora A stabilizes a 
productive conformation of its substrate binding and catalytic 
elements [including the catalytic lysine (Lys 162), the αC helix 
which bears the glutamic acid (Glu 181) that interacts with Lys 162, 
the DFG motif, and the activation loop containing Thr 288] (20, 
28). In contrast, inhibitors, such as VX-680, MLN8054, and 
TaBle 1 | Biochemical inhibition constants of the aurora inhibitor panel.
aurora a aurora a-TPX21–43 aurora B-incenP783–918
Ki
Mean ± sD (nM)
Ki
Mean ± sD (nM)
Ki
Mean ± sD (nM)
VX-680 1.03 ± 0.18 (n=11) 4.55 ± 0.57 (n=9) 1.11 ± 0.20 (n = 9)
MK-5108 <0.01a (n = 4) 0.04 ± 0.008 (n = 3) 1.49 ± 0.21 (n = 3)
MK-8745 0.06 ± 0.004 (n =4) 0.41 ± 0.06 (n =3) 66.8 ± 19.6 (n =3)
MLN8054 0.15 ± 0.01 (n =4) 0.80 ± 0.09 (n = 3) 1.65 ± 0.36 (n = 3)
MLN8237 0.04 ± 0.007 (n =3) 0.23 ± 0.02 (n = 3) 1.10 ± 0.23 (n = 3)
Genentech Aurora Inhibitor 1 0.57 ± 0.06 (n = 3) 0.24 ± 0.02 (n = 3) 156.2 ± 33.7 (n = 3)
ZM447439 55.5 ± 8.2 (n = 4) 336.8 ± 50.5 (n = 3) 1.83 ± 0.28 (n = 3)
AZD1152-HQPA 83.8 ± 14.2 (n = 4) 351.9 ± 64.1 (n=3) 0.02 ± 0.009 (n = 3)
Hesperadin 1.21 ± 0.14 (n = 3) 1.37 ± 0.12 (n = 3) 0.03 ± 0.014 (n = 3)
GSK1070916 16.1 ± 1.3 (n =3) 130.2 ± 33.2 (n =3); 490b 0.38b
aUpper bound.
bValues from Ref. (61).
TaBle 2 | In vitro selectivity ratios of the aurora inhibitor panel (fold difference in potency calculated by dividing Ki values measured for each kinase).
aur a versus  
aur a-TPX21–43
aur a versus  
aur B-incenP783–918
aur a-TPX21–43 versus  
aur B-incenP783–918
aur B-incenP783–918 
versus aur a
aur B-incenP783–918 versus 
aur a-TPX21–43
VX-680 4.4 1.1 0.2 0.9 4.1
MK-5108  >4 >149 39.1
MK-8745 6.3 1030 162
MLN8054 5.5 11.3 2.1
MLN8237 5.5 26.8 4.9
Genentech Aurora 
Inhibitor 1
0.4 274 654
ZM447439 6.1 30 184
AZD1152-HQPA 4.2 3759 15779
Hesperadin 1.1 40.2 45.3
GSK1070916 8.1 42.2 343
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quinazoline-class compounds, favor distorted inactive conforma-
tions of some or all of these elements (59, 71, 73–76). As suggested 
previously for VX-680 and a quinazoline resembling ZM447439 
and AZD1152-HQPA (70), these opposing structural effects likely 
result in the decreased affinities of the majority of the inhibitors 
we characterized for the Aurora A/TPX21–43 complex (Table 2). 
Conversely, based on their respective positions in the Aurora A 
and Aurora B binding pockets, Genentech Aurora Inhibitor I (59) 
and Hesperadin (20) are predicted to make minimal contact with 
the active site elements that move upon TPX21–43 binding. This 
potentially explains the subtle changes in Aurora A Kis for these 
two compounds in the presence of TPX21–43 (Table 2).
From a biochemical selectivity perspective, the Ki shifts driven 
by TPX21–43 binding have important but different consequences for 
the Aurora A- and Aurora B-selective compounds. The selectivity 
ratios of GSK1070916, ZM447439, and AZD1152-HQPA (prefer-
ence for Aurora B over A) increase to ≥184 in the presence of 
TPX21–43 (Table 2). Conversely, the selectivity ratios of the Aurora 
A-selective inhibitors diminish significantly, with MLN8054 
and MLN8237 exhibiting only two- and fivefold preference, 
respectively, for Aurora A/TPX21–43 over Aurora B/INCENP783–918 
(Table 2). Given the prevalent use of MLN8054 and MLN8237 as 
Aurora A-selective tools, these findings motivated us to analyze 
our inhibitor panel in a battery of cellular assays.
substrate Phosphorylation-Based Profiling 
of aurora inhibitors in hela cells
The critical parameters influencing inhibitor choice for cell biolo-
gists are efficacy and specificity in a cellular context. Thus, we next 
focused on identifying robust and reproducible cellular readouts 
for Aurora A and Aurora B kinase activity and employed them to 
systematically profile inhibitors in dose–response in three cell lines 
commonly used in cell biological studies: HeLa cervical carcinoma, 
hTERT-RPE1 retinal pigment epithelial (hereafter referred to as 
RPE1), and U2OS osteosarcoma cells. Based on previous bio-
chemical studies, it is known that many of the inhibitors we tested 
can inhibit Aurora C. However, based on our qPCR analysis and 
previously published work (15), Aurora C mRNA is expressed at 
low levels in HeLa and RPE1 cells, and only present at ~20% of 
Aurora B mRNA levels in U2OS cells (Figure S1A in Supplementary 
Material). Thus, we believe that the biological effects we detect are 
predominantly, if not exclusively, mediated by Aurora A and B.
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As a first approach, we performed immunofluorescence in 
fixed HeLa cells to detect phospho-epitopes associated with the 
activity of each kinase. Aurora A has multiple known substrates 
enriched at centrosomes/mitotic spindles, including the Hippo 
pathway kinase LATS2 (Ser 83) (77), TACC3 (Ser 558) (78–82), 
and Aurora A itself (Thr 288) (16, 17). We chose pLATS2(Ser 83) as 
a cellular readout for Aurora A activity because pilot experiments, 
guided by a prior study (83), indicated that robust, specific labe-
ling could be obtained using a commercial monoclonal antibody 
(Clone ST-3B11) targeting this epitope (Figure  3A). Aurora B 
phosphorylates Ser 10 and Ser 28 in the N-terminal tail of histone 
H3 (84, 85) and reliable antibodies are commercially available for 
detecting these phospho-epitopes in cells (Figure 3A; Table S3 in 
Supplementary Material). We chose pH3(Ser 28) as the model sub-
strate site because robust labeling could be achieved under fixation 
conditions compatible with pLATS2(Ser 83) labeling, allowing us 
to monitor activities of both Aurora A and B in the same cells in 
96-well plates. We used RNAi (Figure 3B) to confirm that pH3(Ser 
28) is sensitive to knockdown of Aurora B but not Aurora A, and 
that pLATS2(Ser 83) is significantly reduced by knockdown of 
Aurora A but not Aurora B (Figures 3B,C); the partiality of the 
RNAi likely accounts for the less-than-complete elimination of 
pLATS2 signal. pH3(Ser 10) behaved similarly to pH3(Ser 28) 
(Figure S1B in Supplementary Material), as expected (84, 85).
We employed the protocol described in Figure 3D to analyze 
substrate phosphorylation in HeLa cells following treatment with 
all 10 inhibitors in dose–response. Asynchronous cells were incu-
bated with vehicle (DMSO) or different inhibitor doses for 8 h and 
then fixed and labeled with a mixture of three antibodies directed 
against pLATS2(Ser 83), pH3(Ser 28), and MPM2 [which detects 
mitotic phosphoepitopes; (86)]. While both the anti-pLATS2(Ser 
83) and MPM2 antibodies are mouse monoclonals, they are of 
different IgG subclasses [IgG2b for anti-pLATS2(Ser 83) and 
IgG1 for MPM2], and can thus be detected with subclass-specific 
secondary antibodies (Table S3 in Supplementary Material).
In control mitotic cells, pLATS2(Ser 83) is concentrated in 
foci around the spindle poles (Figure 3E; top row – green arrow) 
and pH3(Ser 28) is on the mitotic chromatin (Figure  3E; top 
row  –  red arrow). Selective kinase inhibition should result in 
loss of one signal but not the other, as illustrated by the example 
images for specific conditions in Figure 3E (middle and bottom 
rows). Cells were imaged in 4 channels to visualize pLATS2(Ser 
83), pH3(Ser 28), MPM2, and DNA (labeled with Hoechst) and 
mitotic cells were segmented based on their bright MPM2 labe-
ling (Figure 3E). Intensity and area thresholds were set to select 
the pLATS2(Ser 83) foci and the pH3(Ser 28)-labeled chromatin 
in their respective channels in DMSO-treated control cells and 
the same thresholds were applied for inhibitor-treated cells. The 
mean fluorescence intensity per pixel was measured to assess the 
activities of the kinases targeting these two substrate phospho-
rylation sites. The results of this analysis for all 10 inhibitors in 
dose–response are shown in Figure 4A.
Two major conclusions emerging from this dataset are:
 (1) All four Aurora B-selective inhibitors can be used to spe-
cifically and potently inhibit H3(Ser 28) phosphorylation 
in cells. Consistent with the behavior of these compounds 
in the enzymatic assays described above, AZD1152-HQPA, 
Hesperadin, and GSK1070916 are extremely potent, com-
pletely eliminating pH3(Ser 28) labeling without affecting 
pLATS2(Ser 83) labeling at <100 nM concentrations.
 (2) The inhibitors designed to target Aurora A require sig-
nificantly higher concentrations for efficacy and exhibit 
greater variability with respect to specificity. MK-5108 
and MK-8745, two related compounds (Figure 1), achieve 
specific Aurora A inhibition, as demonstrated by loss of 
pLATS2(Ser 83) labeling without reduction of pH3(Ser 28) 
labeling. However, both compounds require high micromo-
lar concentrations for full efficacy (Figure 4A). In contrast, 
and consistent with the biochemical data, the commonly 
used MLN8054 and MLN8237 compounds have narrower 
specificity windows (10- and 4-fold, respectively), which 
makes it difficult to fully inhibit Aurora A without affecting 
Aurora B (Figure 4A). This point is illustrated by example 
images of MLN8054-treated HeLa cells at three different 
concentrations (Figure 4B). With careful optimization, these 
inhibitors can be employed for selective Aurora A inhibition, 
especially if the experimental goal is partial Aurora A inhibi-
tion. However, based on this dataset, MK-5108 and MK-8745 
would be preferred for selectively targeting Aurora A.
Although similar to MK-5108 and MK-8745 in terms of Aurora 
A specificity, Genentech Aurora Inhibitor 1 led to significantly 
reduced proliferation and apoptotic cell death in HeLa cells within 
24 h of treatment (Figures 4C,D; Figure S2A in Supplementary 
Material). This toxicity, which was also observed in U2OS and 
RPE1 cells (Figure 4D), is most likely due to off-target effects, as 
it is not observed with MK-5108, MLN8237, or AZD1152-HQPA 
(Figure 4D; Figure S2B in Supplementary Material). Therefore, the 
narrow window between efficacy and cytotoxicity of Genentech 
Aurora Inhibitor 1 suggests that it should not be used in routine 
cell culture experiments for Aurora A inhibition.
analysis of inhibitor efficacy in rPe1 and 
U2Os cells highlights Variation in Potency 
and specificity across cell lines
We focused on additional characterization of the four inhibitors 
designed to target Aurora A that were not cytotoxic (MLN8054, 
MLN8237, MK-5108, MK-8745; Figure  4D; Figure S2B in 
Supplementary Material), and AZD1152-HQPA and GSK1070916, 
because they are chemically distinct (Figure 1) and the two most 
potent Aurora B inhibitors in the HeLa substrate phosphorylation 
assays (Figure 4A). As a first step, we analyzed substrate phos-
phorylation in RPE1 and U2OS cells for these six compounds 
(Figures 5A,B). This analysis revealed that the specificity window 
for certain inhibitors was significantly narrower in RPE1 and 
U2OS compared to HeLa cells, as best illustrated by MLN8054 
and MLN8237 (compare Figure 5A with Figure 4A). In addition, 
inhibitor potency varied up to fourfold across the three cell lines 
(Figure 5B; Figure S2C in Supplementary Material). Regardless 
of the specific reasons for this variation (discussed below), our 
results underscore the technical importance of performing a 
dose–response analysis with the pLATS2(Ser 83) and pH3(Ser 
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28) labeling assay in all experimental cell lines in order to identify 
the minimum concentration required for selective and complete 
Aurora kinase inhibition. The results of this analysis confirm 
MK-5108 and MK-8745 as the current best Aurora A-specific 
inhibitors, with the latter exhibiting the least effect on pH3(Ser 
28) at doses that eliminate pLATS2(Ser 83) labeling. We addition-
ally note that H3(Ser 28) may be targeted by Aurora C in tissues/
cell types where this kinase is expressed. As Aurora C mRNA is 
present at modest levels in U2OS cells and all pH3(Ser 28) signal 
is abolished by AZD1152-HQPA and GSK1070916 in this cell 
line, we believe any minor Aurora C activity that may be present 
is inhibited by these compounds, a conclusion that is consistent 
with published biochemical studies (46, 47, 61).
Measurement of g2 Duration in a live 
imaging assay enables assessment of 
inhibitor Potency and specificity for 
aurora a
We next characterized the effect of selected inhibitors in single-
cell live imaging assays, which provide high resolution, dynamic 
assessment of kinase function in a cellular context. For this 
purpose, the key challenge was to identify a specific readout 
for each kinase. For Aurora B, cytokinesis failure is a robust 
and well-established cellular phenotype of inhibition, which we 
confirmed with the four Aurora B-specific inhibitors (Figure S3 
in Supplementary Material). However, for Aurora A, a specific 
quantifiable live imaging readout has been lacking. Prior work in 
Xenopus egg extracts (87), Caenorhabditis elegans embryos (88), 
and mammalian cells (89, 90) has suggested a role for Aurora A 
in controlling the kinetics of mitotic entry. Entry into mitosis, as 
defined by nuclear envelope breakdown (NEBD), is delayed in 
the absence of Aurora A. To quantitatively monitor this function 
of Aurora A in living cells, we employed an assay in which eGFP-
tagged PCNA (GFP-PCNA) and mRFP-tagged histone H2B 
(H2B-RFP) are co-expressed and imaged in a cell population 
(91). PCNA concentrates in foci known as replication factories 
in S-phase (Figure 6A; Movie S1 in Supplementary Material) and 
the time interval from dissolution of PCNA foci to NEBD serves 
as a measure of G2 duration in living cells (Figure 6A; Movie S1 in 
Supplementary Material) (91–93). Using this assay in HeLa cells, 
we found that depletion of Aurora A, but not Aurora B, by RNAi 
significantly increased G2 duration (Figure 6B). We next meas-
ured G2 duration in HeLa cells following treatment with MK-5108 
and AZD1152-HQPA, at concentrations that selectively eliminate 
labeling of pLATS2(Ser 83) or pH3(Ser 83), respectively (6 μM 
for MK-5108 and 100 nM for AZD1152-HQPA; Figure 4A). In 
agreement with the RNAi analysis, MK-5108, but not AZD1152-
HQPA, significantly increased G2 duration (Figure  6C). Thus, 
measurement of G2 duration using the GFP-PCNA; H2B-RFP 
imaging assay provides a specific functional readout for Aurora 
A activity in living cells.
We next performed a dose–response analysis of the inhibi-
tors developed to target Aurora A in the G2 duration assay in 
HeLa, RPE1, and U2OS. The results are shown in Figure  7 
(and Figure S4 in Supplementary Material) and highlight that 
measurement of G2 duration with this assay provides a sensitive 
and dose-responsive measure for Aurora A activity in cells. The 
concentrations where G2 duration was maximally extended 
by Aurora A inhibitors tracked well with the concentrations at 
which pLATS2(Ser 83) labeling was eliminated (see Table 3 and 
text below). This concordance between distinct cell-based assays 
confirms that each assay specifically monitors Aurora A activity 
and gives us confidence that the inhibitor characterization 
performed using them is providing an accurate picture of 
efficacy in a cellular context.
immunoblotting-Based assessment of 
inhibitor Potency and specificity
Next, we sought to compare the inhibitor potency and specificity 
measurements obtained using the cellular assays to more proximal 
markers of cellular activity – namely phosphorylation of Aurora 
A and Aurora B. We developed methods to monitor kinase 
phosphorylation by immunoblotting because we found it to have 
higher signal-to-noise and greater consistency than immuno-
fluorescence. For this analysis, we focused on the four inhibitors 
with the best overall cellular profiles as Aurora A-selective (MK-
5108, MK-8745) or Aurora B-selective (AZD1152-HQPA and 
GSK1070916). After treating cells with different concentrations of 
these inhibitors, we performed Western blotting for eight targets 
for which commercial antibodies are available – pAuroraA(Thr 
288), pAuroraA(Thr 288)/pAuroraB(Thr 232)/pAuroraC(Thr 
198), total Aurora A, total Aurora B, pH3(Ser 28), pH3(Ser 
10), total H3, and Cyclin B. We did not assess pLATS2(Ser 83), 
because the antibody used for immunofluorescence did not work 
well for immunoblots. The specific antibodies used for immu-
noblotting were selected based on extensive testing, employing 
both siRNA depletion (to assess specificity; Figure  3A; Figure 
S5 in Supplementary Material) and inhibitor treatments (to 
confirm detection of phospho-epitopes; Figures 8A,B); see Table 
S3 in Supplementary Material for descriptions and supplier 
information.
For analysis of the Aurora A-selective compounds, 
MK-5108 and MK-8745, we employed the protocol outlined in 
Figure  8A, based on taxol-induced mitotic checkpoint arrest. 
For analysis of Aurora B-selective inhibitors, AZD1152-HQPA 
and GSK1070916, we modified a previously described protocol 
[outlined in Figure 8B; (94)] whose design reflects the fact that 
Aurora B inhibition overrides taxol-induced arrest (44, 45). To 
ensure a fair comparison between different conditions, we immu-
noblotted Cyclin B to confirm that a similar number of mitotic 
cells were present in the analyzed lysates, in addition to blotting 
for total H3 as a general loading control. While optimizing the 
immuoblotting assays, we found that pAuroraA(Thr 288) exhib-
ited low solubility compared to total Aurora A, pAuroraB(Thr 
232), or total Aurora B in a typical cell lysis buffer containing 
non-ionic detergent; only with extensive sonication were we 
able to solubilize the pAuroraA(Thr 288) signal. This observa-
tion suggests that autophosphorylated Aurora A is associated 
with insoluble cytoskeletal elements, possibly microtubules or 
centrosomes. From a technical perspective, this observation 
highlights the importance of employing lysate preparation 
conditions that properly solubilize pAuroraA(Thr 288) in order 
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to avoid false negative results and/or overestimates of inhibitor 
potencies. In  situations where changes in cell number/viability 
are not expected (obviating the need to normalize loading by 
measuring lysate protein concentrations), samples could be 
prepared by lysing cells directly with SDS gel sample buffer.
The immunoblotting analysis of autophosphorylated Aurora 
A, pH3(Ser 28), and pH3(Ser 10), confirmed the specificity of 
MK-5108 and MK-8745 for Aurora A and AZD1152-HQPA and 
GSK1070916 for Aurora B. At concentrations of MK-5108 and 
MK-8745 that completely eliminate Thr 288 phosphorylation 
(and pLATS2(Ser 83) signal in the fixed immunofluorescence 
assay), there is no effect on pH3(Ser 10), pH3(Ser 28), or 
pAuroraB(Thr 232) (Figure 8A). Reciprocally, AZD1152-HQPA 
and GSK1070916 eliminated pH3(Ser 10), pH3(Ser 28), 
and pAuroraB(Thr 232) at concentrations that did not affect 
pAuroraA(Thr 288) (Figure 8B).
For AZD1152-HQPA and GSK1070916, there was strong cor-
respondence between the concentration-dependent effects on H3 
and Aurora B phosphorylation with those observed in the immu-
nofluorescence and cytokinesis assays (Figures 4A and 8B; Figure 
S3 in Supplementary Material; Table 3). However, for MK-5108 
and MK-8745, complete loss of Aurora A Thr 288 phosphorylation 
was observed at significantly lower inhibitor concentrations than 
those necessary for full efficacy in the LATS2 phosphorylation 
and G2 duration assays [(IC50 pAuroraA(Thr 288) <<100  nM 
versus IC50 pLATS2 (Ser 83) and G2 duration: ~ 600-800 nM)] 
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(Figures 4A, 7 and 8A; Table 3). There are three potential expla-
nations for this difference. First, the immunoblotting of activation 
loop phosphorylation, at least for Aurora A under the conditions 
employed here, may have a significantly lower dynamic range 
than the two cell-based assays. Second, the phosphatases that 
remove pAuroraA(Thr288) (27, 95, 96) may be more efficient 
than those that reverse pLATS2(Ser 83) and the Aurora A 
phosphorylation target(s) that contribute to G2 duration control. 
TaBle 3 | cellular inhibitory potencies of the aurora inhibitor panel.
aurora kinase inhibitor cell line assay
substrate-phosphorylation g2/M cytokinesis
pLATS2 (Ser83) pHistone H3 (Ser28)
IC50 (nM) IC50 (nM) IC50 (nM) IC50 (nM)
VX-680 HeLa 150 45 nd nd
RPE1 nd nd nd nd
U2OS nd nd nd nd
MK-5108 HeLa 610 NE@9 μM 816 nd
RPE1 1800 80% Inh @15 μM 877 nd
U2OS 1200 20% Inh @15 µM 995 nd
MK-8745 HeLa 610 NE@9 µM 596 nd
RPE1 2300 NE@15 µM 755 nd
U2OS 1700 NE@15 µM 437 nd
MLN8054 HeLa 290 2900 736 nd
RPE1 720 880 500 nd
U2OS 800 3300 957 nd
MLN8237 HeLa 37 160 128 nd
RPE1 130 130 115 nd
U2OS 92 210 157 nd
Genentech Aurora Inhibitor 1 HeLa 490 NE@9 μM nd nd
RPE1 nd nd nd nd
U2OS nd nd nd nd
ZM447439 HeLa NE@3 μM 419 nd 615
RPE1 nd nd nd 1315
U2OS nd nd nd 613
AZD1152-HQPA HeLa NE@100 nM 5 nd 4
RPE1 NE@200 nM 25 nd 23
U2OS NE@200 nM 12 nd 20
Hesperadin HeLa NE@100 nM 14 nd 14
RPE1 nd nd nd 47
U2OS nd nd nd 17
GSK1070916 HeLa NE@100 nM 6 nd 6
RPE1 NE@200 nM 15 nd 21
U2OS NE@200 nM 8 nd 6
NE, no effect; nd, not determined.
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Third, this difference may arise from cellular Aurora A existing 
in multiple active but biochemically distinct forms, as proposed 
previously (28, 32). Recent biochemical data indicate that Thr 288 
phosphorylation is not a prerequisite for Aurora A kinase activity 
if Aurora A is bound to TPX2 (28, 32). Further, our in vitro studies 
indicate that Aurora A/TPX2 is more difficult to inhibit than the 
free enzyme. Therefore, if LATS2 phosphorylation and mitotic 
entry kinetics are dependent upon Thr 288 unphosphorylated but 
active pools of Aurora A (bound to activators), sole assessment 
of Thr 288 phosphorylation may provide a misleading view of 
inhibitor potencies. Additional studies will be required to explore 
these possibilities.
Regardless of the underlying reasons, our data highlight that if a 
pAuroraA(Thr 288) immunoblot was employed with pH3 immu-
nofluorescence/immunoblots to characterize inhibitor effects, 
one would conclude that MK-5108 and MK-8745 completely 
block cellular Aurora A activity at much lower concentrations 
than we measure for the pLATS2(Ser 83) immunofluorescence 
and live cell G2 duration assays, and that MK-5108 and MK-8745 
have significantly greater selectivity in a cellular context than 
is actually the case. Thus, we caution on relying exclusively on 
immunoblotting, especially with activation loop phosphorylation 
antibodies for Aurora A, to measure inhibitor potency and speci-
ficity. Instead, we recommend performing quantitative fixed or 
live imaging-based analysis of kinase activity, and complement-
ing with immunoblotting.
synthesis of Biochemical and cellular 
Profiling Data to identify the Best aurora 
a- and B-selective inhibitors
Differences in ATP concentrations (biochemical – micromolar; 
cellular milieu – millimolar) as well as compound solubility/sta-
bility, binding to serum proteins in media, and cellular penetra-
tion make direct correlation of biochemical and cellular inhibitor 
potencies difficult (97). However, the Aurora A/B selectivity ratios 
derived from our in vitro and in vivo data can be compared to 
prioritize inhibitors. In the biochemical assays, AZD1152-HQPA, 
ZM447439, Hesperadin, and GSK1070916 all exhibit >30-fold 
selectivity for Aurora B/INCENP783–918 over Aurora A and Aurora 
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A/TPX21–43 (Table 2). This selectivity is recapitulated in the cellular 
analysis. Complete inhibition of Aurora B(Thr 232) and H3(Ser 
28) phosphorylation (as well as blockade of cytokinesis) can be 
achieved with each of these compounds in the absence of any 
effect on Aurora A(Thr 288) or LATS2(Ser 83) phosphorylation 
(Table 3). So, which of these compounds is the best for cell biology 
experiments? Hesperadin is potent and specific but appears to be 
unstable under long-term live imaging conditions (see legend of 
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Figure S3 in Supplementary Material). Within the quinazoline 
class of compounds (Figure 1), AZD1152-HQPA is preferable as 
it is approximately two orders of magnitude more potent in vitro 
and in  vivo than ZM447439, from which it was derived. How 
then do AZD1152-HQPA and GSK1070916 compare? Although 
both are selective, AZD1152-HQPA exhibits significantly greater 
preference for Aurora B/INCENP783–918 when compared to either 
Aurora A or Aurora A/TPX21–43 in  vitro (Table  2). Consistent 
with this, immunoblotting revealed that, while both compounds 
eliminated Aurora B activity at <100 nM without affecting pAu-
roraA (Thr 288) (Figure  8), at 300  nM GSK1070916 inhibited 
Aurora A activity whereas AZD1152-HQPA did not (Figure S6 
in Supplementary Material). In addition, when profiled against 
363 human kinases (including Aurora A/B/C) at 100 nM concen-
tration (Table S4 in Supplementary Material), both compounds 
exhibited high Aurora kinase-specificity but AZD1152-HQPA 
was slightly superior. Aurora B was the only enzyme inhibited 
≥65% of control by AZD1152-HQPA whereas Aurora A and B 
as well as DDR1 are inhibited by GSK1070916 at or above this 
threshold (Table S4 in Supplementary Material). Therefore, we 
believe that AZD1152-HQPA is the current best choice for an 
Aurora B-selective inhibitor, and recommend use of GSK1070916 
for confirmatory follow-up studies (see below).
In terms of the Aurora A inhibitors, MLN8054 and MLN8237 
exhibit only modest selectivity in vitro and in vivo (Tables 2 and 
3). Genentech Aurora Inhibitor I is cytotoxic within the range of 
concentrations required for full inhibition of Aurora A activity 
(Figure 4D). In the fixed and live imaging cell-based assays, the 
two Merck compounds were similar with MK-5108 being slightly 
more potent (Table 3) and MK-8745 being more selective in both 
RPE1 and U2OS cells (Figure 5; Table 3). By kinome profiling 
analysis, MK-8745 was significantly more Aurora kinase-specific. 
At 100 and 500  nM, MK-5108 inhibited 32 and 75 kinases 
(including the Aurora kinases), respectively, at >65% of control; 
Polo-like kinase 4 was the only cell cycle-related kinase affected 
(Table S4 in Supplementary Material). In contrast, MK-8745 at 
500  nM only inhibited 16 kinases at >65% of control (Aurora 
A, AXL, BRK, DDR1, EphA6, GSK3α/β, IRAK1, JNK1, LKB1, 
ROS1, Trk A/B/C, TYRO3, YES). Thus, based on its Aurora and 
off-target selectivity, we believe that MK-8745 is the current best 
commercially available Aurora A-selective inhibitor for cellular 
studies.
The structure of the aurora a Kinase 
Domain Bound to MK-5108 reveals 
Features Underlying Potency and 
specificity
To gain insight into the remarkable biochemical potency and 
Aurora A-selective nature of the MK-8745/MK-5108 class of 
compounds, we determined the 2.2 Å X-ray crystal structure of the 
human Aurora A kinase domain bound to MK-5108 (Figure 9A; 
Table S5 and Figure S7 in Supplementary Material). In the inhibi-
tor complex, the Aurora A kinase domain adopts an inactive 
conformation in which both the αC helix (orange; Figure 9A) and 
particularly the activation loop (yellow; Figure 9A) are improperly 
positioned for catalysis (Figure 9B – compare MK-5108-bound 
versus ADP-bound structures). Electron density maps indicate 
that both Thr 287 (which adopts two alternate conformations; 
only one is illustrated) and Thr 288 are phosphorylated, show-
ing that the inhibitor is able to interact with the activated form 
of the enzyme (Figure  9A). Consistent with its action as an 
ATP-competitive inhibitor (56), MK-5108 inserts itself into 
the nucleotide-binding pocket between the two lobes of the 
kinase in the same orientation as its parent compound VX-680 
(Figures 9A,B).
The picomolar affinity of MK-5108 for Aurora A is explained 
by the extensive polar and van der Waals interactions it forms 
with 22 residues throughout the active site (Figure  9C, Table 
S6 in Supplementary Material). The aminothiazole moiety 
(Figures  9C,D) is located adjacent to the gatekeeper residue 
Leu 210 enabling it to form two hydrogen bonds with the main 
chain amide nitrogen and carbonyl of Ala 213 within the hinge 
region (Figure 9C), thereby making it functionally analogous to 
the aminopyrazole moiety of VX-680 (Figure 9D). The 2-fluoro, 
3-chlorophenol on the opposite end of the inhibitor (Figure 9D) 
packs against the side chains of the catalytic lysine (Lys 162), 
precluding its active conformation, as well as against Phe 275 of 
the DFG motif (Figure 9C). This interaction stabilizes a flipped, 
inactive conformation of the DFG motif that is intermediate 
between the active “DFG-in” state (Figure 9B – ADP-bound) (98) 
and the canonical “DFG-out” conformation (99). This conforma-
tion is distinct from the distorted conformation in the VX-680 
Aurora A complex (Figure 9B – VX-680-bound) (74), and the 
“DFG-up” conformation linked to MLN8054 binding (59, 71, 
75), and resembles that of Aurora A bound to adenosine (PDB: 
1MUO) (100). Importantly, the 2-fluoro, 3-chlorophenol moiety 
of MK-5108 forms a likely highly energetically favorable edge-
face aromatic pi stacking interaction with the indole of Trp 277 
(Figures 9C,D). Because of the major differences in its chemical 
structure in this region (Figure 9D), VX-680 only forms hydro-
phobic contacts with Phe 275 (via its cyclopropylamide) and not 
Trp 277 (Figure 9B). The interaction between MK-5108 and the 
side chain of Trp 277 has the effect of “pinning down” the activation 
loop at its N-terminal end and disfavors its adoption of an active 
conformation (Figure 9B). We note that the phosphates on Thr 
287 and Thr 288 form hydrogen bonds with the side chains of His 
187 and Lys 250, respectively, from a symmetry-related molecule. 
However, since residues 281–285 are disordered (Figure 9B), we 
believe that residues 277–280 should not be constrained by these 
contacts, and that their positioning is a consequence of inhibitor 
binding. The inactive conformation of the activation loop that 
we describe here is, to our knowledge, unique among all known 
human Aurora A kinase domain – inhibitor complex structures. 
The conformations of the active site and activation loop residues 
stabilized by MK-5108 binding are distinct from those favored 
by TPX2 binding, which likely explains the reduced affinity of 
MK-5108 for the Aurora A/TPX21–43 complex.
The crystal structure of the MK-5108/Aurora A complex also 
suggests a potential explanation for the selectivity of this inhibi-
tor. MK-5108 interacts with the side chains of two (Thr 217 and 
Arg 220) of the four residues in the vicinity of the active site that 
differ between Aurora A and B (Aurora A: Ala 141, Leu 215, 
Thr 217 and Arg 220; Aurora B: Lys 85, Arg 159, Glu 161, Lys 
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164) (Figure 9C; Table S6 in Supplementary Material). Although 
the electron density for Aurora A Arg 220 is weak (indicative of 
mobility), the positively charged guanidinium of this residue is 
located close enough to the negatively charged MK-5108 carbox-
ylate to form favorable electrostatic interactions (Figures 9C,D). 
However, the equivalent Aurora B residue is a lysine (Lys 164), 
which should also be able to form the same types of interactions. 
In contrast, the side chain of Thr 217 is wedged in between the 
carboxylate and the cyclohexyl ring of MK-5108 (Figures 9C,D). 
This tight fit would not be possible with the equivalent Glu 161 in 
Aurora B, likely significantly reducing binding affinity. Integrated 
mutagenesis, biochemical and structural studies of MLN8054 
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and Genentech Aurora A Inhibitor I (which both pack against 
Thr 217) have indicated that Thr 217 contributes heavily to the 
selectivity of these compounds (59, 71, 75). Equivalent efforts 
with MK-5108 and MK-8745 (which, by modeling, is predicted 
to bind in a highly similar manner as MK-5108 to the Aurora 
A active site) will be necessary to test if Thr 217 is the central 
determinant of Aurora A/B selectivity for these compounds, 
as suggested by our structural analysis.
DiscUssiOn
The current tool chest of Aurora inhibitors is the product of 
extensive chemical optimization in the pursuit of suitable clinical 
candidates, rather than optimal inhibitors for cell biology stud-
ies. As a consequence, careful comparison of these inhibitors 
in parallel biochemical and cell-based assays has been lacking. 
The systematic profiling data presented here should provide a 
resource for future studies employing these compounds. Based 
on our results, we provide the following ‘good practice’ guidelines 
with respect to their use:
 (1) pH3(Ser 28) and pLATS2(Ser 83) labeling, which we validate 
as specific cellular readouts for Aurora B and A, respectively, 
provides a convenient and robust means to characterize 
existing and newly developed Aurora kinase inhibitors, and 
should be used prior to any detailed functional analysis con-
ducted with this class of compounds. Inhibitor sensitivity can 
be modulated by biological factors (such as kinase expression 
levels) or technical factors (such as changes in serum/media 
and growth conditions) (97). Hence, dose–response analysis 
employing the pH3(Ser 28)/pLATS2(Ser 83) labeling assay is 
particularly important when extending inhibitor use to new 
cell lines not analyzed here. While we present a large dataset 
for HeLa, RPE1, and U2OS cells that should serve as a bench-
mark for future studies, we still recommend performing a 
dose–response even when using these three lines given inter-
lab variability. The goal of such preliminary analysis should 
be to identify the minimum concentration that achieves 
complete inhibition of the relevant marker without affecting 
the other. We strongly advise against the “more is better” 
urge as unnecessarily high doses will likely lead to loss of 
specificity and potential unanticipated off-target effects.
 (2) AZD1152-HQPA is a highly potent, selective, and efficacious 
Aurora B inhibitor and the best current choice for targeting 
this kinase. While AZD1152-HQPA does not exhibit any 
obvious effects against any of the other kinases that we tested, 
this profiling exercise was not exhaustive. Further, there is 
relatively little published about binding of this compound to 
non-kinase proteins, and even very well-characterized mol-
ecules can have unexpected off-target effects. For example, 
recent studies have revealed that the commonly used Plk1 
inhibitor, BI-2536, and several other known kinase inhibi-
tors, are potent inhibitors of BET bromodomain proteins 
(101–103). Therefore, we highly recommend that any results 
from studies using AZD1152-HQPA be corroborated with 
GSK10701916, which likely has a different off-target profile 
based on its unrelated chemical structure. Indeed, this 
strategy of using structurally distinct compounds with com-
mon mechanisms should be applied when using any of the 
inhibitors analyzed here and when performing chemical cell 
biology studies in general.
 (3) MK-8745 represents the best current commercially available 
option for selective and potent Aurora A inhibition. We note, 
however, that the lowest concentration of MK-8745 that is 
necessary to maximally inhibit Aurora A in cells is >100-fold 
higher than the lowest concentration of AZD1152-HQPA 
that is necessary to fully inhibit Aurora B. Hence, based on 
current chemical biology standards [on-target cellular activ-
ity <1 μM; (104, 105)], AZD1152-HQPA is an ideal chemical 
tool whereas MK-8745 is not. In addition, validation of any 
findings with MK-8745 with an orthogonal chemical scaffold 
is not currently straightforward. If only partial inhibition of 
Aurora A is required, MLN8054 (and possibly MLN8237) 
could be used but only under carefully controlled circum-
stances. Alternatively, MK-5108 could be used but this is 
also not optimal given its chemical similarity to MK-8745. 
In the recent literature, at least five classes of compounds 
with Aurora A-selective behavior (which are not commer-
cially available or only became available near the end of this 
study) have been reported (106–110). Assessment of these 
inhibitors should reveal if one or more of them can be paired 
with MK-8745 for analysis of Aurora A function in cellular 
experiments.
 (4) Immunoblotting of activation loop phosphorylation should 
not be used in isolation to estimate inhibitor potency 
and specificity. As we show here, immunoblotting with 
pAuroraA(Thr 288) antibodies suggests significantly higher 
Aurora A inhibitor potency than is observed in validated 
fixed and live imaging-based cellular assays. Consequently, 
if only immunoblotting were performed, one could over-
estimate not just potency but also selectivity for Aurora 
A versus Aurora B. We recommend that the fixed or live 
imaging-based cellular assays described here be employed 
first, with immunoblotting serving as confirmation. The 
imaging-based cellular assays also have the advantage of 
revealing potential off-target effects, such as the toxicity of 
the Genentech Aurora Inhibitor 1 reported here.
Our analysis highlights that, while highly selective and potent 
tools for Aurora B inhibition are readily available, there is sig-
nificant room for improved small molecule inhibitors of Aurora 
A. Part of the challenge in targeting Aurora A likely arises from 
its multiple activation mechanisms, which makes uniformly 
inhibiting the different active states of the kinase difficult. A 
second limitation is the prior lack of a consistent and rigorous 
assay paradigm for Aurora A activity in a cellular context – as 
we show here, immunoblotting of activation loop phosphoryla-
tion can be misleading when compared to other kinase activity 
readouts – a fact that can be rationalized by recent findings that 
activation loop phosphorylation is not essential for high levels 
of kinase activity in the presence of an activator such as TPX2. 
Our findings suggest new avenues to help address the challenge of 
developing a more potent and highly selective Aurora A inhibitor. 
First, the pLATS2(Ser 83) and the G2 duration assays provide 
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independent, robust, and dose-responsive cellular readouts that 
specifically report on Aurora A but not Aurora B activity. These 
assays could be used for optimization of novel classes of Aurora 
A inhibitors in a cell-based context, analogous to the strategy we 
employed recently to develop a Plk4 inhibitor, centrinone, that 
prevents centriole duplication (92). The target specificity of cen-
trinone was confirmed through the extensive use of an engineered 
inhibitor-resistant mutant. Analogous approaches could also be 
applied using previously described inhibitor-resistant Aurora 
kinase mutants (75, 111, 112). Further, the crystal structure of 
the MK-5108/Aurora A kinase domain complex we determined, 
which revealed a previously unobserved protein conformation 
and active site interactions, could be used to generate more 
potent versions of MK-5108/MK-8745 and potentially design 
new molecules as well. Given the renewed interest in Aurora A 
as a drug target based on the recently discovered role of Aurora 
A in controlling c-Myc protein levels in cancers such as neuro-
blastoma (113, 114), new inhibitor discovery efforts leveraging 
the approaches described here could aid not only in developing 
better tools for cell biology experiments but also in fully realizing 
the therapeutic potential of inhibiting Aurora A.
MaTerials anD MeThODs
inhibitors and antibodies
Inhibitors and antibodies used in this study are described in Table 
S1 and S3 in Supplementary Material, respectively.
Kinase assays
For the Aurora A assays, purified full-length human Aurora A 
(Millipore) was diluted to ~0.8 nM (based on enzyme activity) in 
7.5 μL of a buffer containing 50 mM Tris (pH 7.5), 150 mM NaCl, 
270 mM sucrose, 0.03% Brij 35, and 1 mM DTT in Corning #4512 
white 384-well plates. Inhibitors arrayed in dose–response were 
added from DMSO stocks using a V&P 384-pintool head mounted 
on a Beckman Multimek chassis. Reactions were then initiated 
via the addition of 7.5 μL of a buffer containing 50 mM Tris (pH 
7.5), 20 mM MgCl2, 1 mM DTT, 0.2 mg/ml BSA, 70 μM ATP, and 
800 μM Kemptide (amino acid sequence: LRRASLG (InnoPep)) 
using a NSX-384 384-channel liquid handler (Nanoscreen), 
and allowed to proceed for 2 h at 25°C. The final reaction buffer 
contained 50 mM Tris (pH 7.5), 10 mM MgCl2, 75 mM NaCl, 
135 mM sucrose, 0.015% Brij 35, 1 mM DTT, 0.1 mg/mL BSA, 
35 μM ATP, and 400 μM Kemptide. The final [ATP] in the reac-
tion mix (35 μM) is at the Km(ATP) for Aurora A. Detection using 
a 5 μL aliquot of each reaction was performed with ADP-GloTM 
reagents (Promega), following the manufacturer’s instructions, 
in PerkinElmer #6008281 plates. Luminescence was measured 
on an Infinite M1000 plate reader (Tecan). Data were fit using a 
4-parameter, variable slope fit in Prism (GraphPad), and Kis were 
calculated from IC50 data using the equation in Figure 2B.
For the Aurora A/TPX21–43 assays, purified full-length human 
Aurora A (Millipore) was diluted to ~0.8 nM (based on enzyme 
activity) in 7.5 μL of a buffer containing 80 nM TPX21–43 (InnoPep), 
50 mM Tris (pH 7.5), 150 mM NaCl, 270 mM sucrose, 0.03% Brij 
35, and 1 mM DTT in Corning #4512 white 384-well plates. The 
TPX21–43 concentration was determined using a calculated molar 
extinction coefficient (280  nm) of 8480 M−1  cm−1. Inhibitors 
arrayed in dose–response were added from DMSO stocks using a 
V&P 384-pintool head mounted on a Beckman Multimek chas-
sis. Reactions were then initiated via the addition of 7.5 μL of a 
buffer containing 50 mM Tris (pH 7.5), 20 mM MgCl2, 1 mM 
DTT, 0.2 mg/ml BSA, 6 μM ATP, and 1,200 μM Kemptide using a 
NSX-384 384-channel liquid handler (Nanoscreen), and allowed 
to proceed for 1 h at 25°C. The final reaction buffer contained 
50  mM Tris (pH 7.5), 10  mM MgCl2, 75  mM NaCl, 135  mM 
sucrose, 0.015% Brij 35, 1  mM DTT, 0.1  mg/mL BSA, 3  μM 
ATP, and 600 μM Kemptide. The final [ATP] in the reaction mix 
(3 μM) is at the Km(ATP) for Aurora A/TPX21–43. At the final 
concentration of 40 nM, TPX21–43 is >10 times the concentration 
required to achieve half-maximal activation of Aurora A under 
these reaction conditions (3 nM) and the previously reported Kd 
of TPX21–43 [2.3  nM (70)]. Detection, measurement, and data 
analysis were performed as described above.
For the Aurora B/INCENP783–918 assays, purified full-length 
human Aurora B/INCENP783–918 (SignalChem) was diluted 
to ~0.5 nM (based on enzymatic activity) in 12 μL of a buffer 
containing 31.25 mM Tris (pH 7.5), 12.5 mM MgCl2, 93.75 mM 
NaCl, 168.75 mM sucrose, 0.0125% Tween 20, 0.625 mM DTT, 
0.1875 mg/mL BSA, and 500 μM Kemptide in Corning #3657 
clear 384-well plates. Inhibitors arrayed in dose–response 
were added from DMSO stocks using a V&P 384-pintool head 
mounted on a Beckman Multimek chassis. After 15 min at 25°C, 
reactions were initiated via the addition of 3 μL of 50 μM ATP 
using a NSX-384 384-channel liquid handler (Nanoscreen), 
and allowed to proceed for 1 h at 25°C. The final reaction buffer 
contained 25 mM Tris (pH 7.5), 10 mM MgCl2, 75 mM NaCl, 
135 mM sucrose, 0.01% Tween 20, 0.5 mM DTT, 0.15 mg/mL 
BSA, 10 μM ATP, 400 μM Kemptide. The final [ATP] in the reac-
tion mix (10 μM) is at the Km(ATP) for Aurora B/INCENP783–918. 
Detection, measurement and data analysis were performed as 
described above.
Radiometric assay-based kinome profiling of AZD1152-
HQPA, GSK1070916, MK-5108 and MK-8745 was performed 
by Reaction Biology Corporation (Malvern, PA, USA) using 
[ATP] ~ Km(ATP) for all enzymes.
cell lines
RPE1 (hTERT-immortalized RPE cells) and U2OS osteosarcoma 
cells were obtained from ATCC. HeLa cervical carcinoma cells 
were from a laboratory stock. RPE1 cells were maintained in 
Dulbecco’s modified Eagle’s medium (DMEM)/F12 plus glu-
tamine medium supplemented with 10% fetal bovine serum, 100 
U/mL penicillin and 100 μg/mL streptomycin. U2OS and HeLa 
cells were maintained in DMEM + Glutamax supplemented with 
10% fetal bovine serum, 100  U/mL penicillin and 100  μg/mL 
streptomycin.
For generation of HeLa, U2OS, and RPE1 lines co-express-
ing H2B-RFP and either GFP-PCNA or YFP-tubulin, cells 
were infected first with an H2B-RFP expressing retrovirus. 
A pBABE-puro vector, encoding human histone H2B with 
mRFP1.3 fused at its C-terminus (H2B-RFP) obtained from 
the laboratory of Don Cleveland, and pBSK-VSV-G were 
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co-transfected into the packaging cell line GP2-293 (Clontech) 
using FuGENE HD (Promega). Virus-containing culture 
supernatant was collected 48 h after transfection and added to 
the growth medium of cells, followed by addition of Polybrene 
(Millipore) to 8 μg/ml.
An MGC collection human PCNA cDNA with eGFP fused 
at its N-terminus (GFP-PCNA) was cloned into pBABE-hygro. 
A pBABE-bla (blasticidin) vector encoding human alpha 1B 
tubulin with eYFP fused to its N-terminus (YFP-tubulin) was 
obtained from the laboratory of Don Cleveland. Virus production 
and infection of cells previously transduced with H2B-RFP was 
performed similarly. FACS was used to select cell populations 
expressing transgenes at moderate levels.
rnai
HeLa cells co-expressing GFP-PCNA and H2B-RFP were used 
for all imaging-based RNAi experiments. ON-TARGETplus 
SMARTpool siRNAs (GE Healthcare) targeting Aurora A and 
Aurora B, as well as a non-targeting control pool, were trans-
fected into cells using Lipofectamine RNAiMAX (Thermo Fisher 
Scientific) at a final concentration of 50  μM in 6-well plates. 
Five hours after transfection, cells were trypsinized and seeded 
into a 96-well cycloolefin plate (Greiner) at 10,000 cells/well in 
fresh medium supplemented with 2.5 mM thymidine. Cells were 
incubated in the presence of thymidine for 18–20  h, and then 
300  ng/mL nocodazole for 6  h. Knockdown was confirmed by 
immunoblotting with the Aurora kinase antibodies specified in 
Table S3 in Supplementary Material and an anti-tubulin antibody 
(DM1A; 1:1000; Sigma).
For fixed analysis to quantify pLATS2(Ser 83), pH3(Ser 10), 
and pH3(Ser 28) intensities, plates were washed twice with fresh 
medium and returned to the incubator for 8 h. Cells were then 
fixed with either 4% PFA =  paraformaldehyde (in phosphate-
buffered saline, PBS) (for pH3 analysis) or 100% ice-cold metha-
nol (for pLATS2 analysis). The following primary antibodies were 
used: pLATS2(Ser 83) (see Table S3 in Supplementary Material); 
pH3(Ser 10) (1:100; Cell Signaling); pH3(Ser 28) (see Table S3 
in Supplementary Material). Cells were imaged on the CV7000 
spinning disk confocal system (Yokogawa Electric Corporation) 
using a 40 ×  0.95 NA U-PlanApo objective and 2560 ×  2160 
sCMOS camera with 2 × 2 binning. 5 μm × 2 μm z-sections of 50 
fields/well were imaged, with replicate wells per RNAi condition.
For quantification, maximum intensity projections were 
generated by the CV7000 acquisition software and transferred 
to ImageJ for analysis. For pLATS2(Ser 83) measurements, the 
integrated signal from a 10 ×  10 pixel box centered on each 
mitotic spindle pole was measured. For background subtraction, 
a 10 × 10 pixel box in the cytoplasm was used. Mean values of 
measurements were normalized to the control RNAi condi-
tion. A total of 186–230 measurements from two independent 
experiments were made. For pH3(Ser 10) and pH3(Ser 28), the 
DNA signal was used to threshold and define a binary mask, 
which was transferred to the pH3 channel. The mean intensity 
of this region was then measured in the pH3 channel. For 
background subtraction, the masked region was expanded by 
20 pixels, and the mean intensity of the peripheral region was 
used. Mean values of measurements were normalized to the 
DMSO-treated condition. A total of 88–147 measurements from 
three  independent  experiments were made.
For live imaging experiments to measure G2 duration, plates 
were washed twice with fresh medium, and immediately mounted 
onto the CV1000 spinning disk confocal system (Yokogawa 
Electric Corporation). The imaging chamber was maintained 
at 37°C and 5% CO2. Cells were imaged using a 20 × 0.75 NA 
U-PlanApo objective and 512 × 512 EM-CCD camera with 2 × 2 
binning. Twelve fields/well were imaged, with 4 replicate wells 
per RNAi condition. 3 μm × 2 μm z-sections in the GFP (25% 
power, 200  ms, 35% gain) and RFP (20% power, 200  ms, 35% 
gain) channels were captured in each field, at 12-min intervals 
for 24 h. Quantification was performed as described in the G2 
duration assay section (see below).
cellular Proliferation analysis
Eight thousand HeLa cells, 8,000 U2OS cells or 4,000 RPE1 cells 
were seeded into white 96-well assay plates (Corning #3610) 
16  h before inhibitor addition. All inhibitors were diluted in 
DMSO and added to cells in complete growth media (2× desired 
concentrations were prepared in complete growth medium and 
added to wells). After 24 h, relative cell number was measured 
using ATPLiteTM reagent (PerkinElmer) following the manufac-
turer’s instructions. DMSO-treated cells were used as controls. 
Two independent experiments with triplicate measurements per 
condition were performed. Luminescence was measured on an 
Infinite M1000 plate reader (Tecan).
live cell-activated caspase 3/7 assay
HeLa cells (6,000/well) were seeded in 96-well μCLEAR plates 
(Greiner) in 100 μL DMEM plus serum, and incubated for 16 h at 
37°C and 5% CO2. MK-5108 and Genentech Aurora Inhibitor 1 
were diluted 1:100 from DMSO stocks into serum-free DMEM 
and 11 μL of the diluted compound was added to cells. After 24 h 
2 μM CellEvent Caspase-3/7 Green Reagent (Life Technologies), 
and NucBlue Live ReadyProbes Reagent (Hoechst 33342; Life 
Technologies) were added. Cells were imaged after 60  min on 
a CV7000 spinning disk confocal system (Yokogawa Electric 
Corporation) with a 20  ×  0.75 NA U-PlanApo objective and 
2560 ×  2160 sCMOS camera with 2 ×  2 binning. The imaging 
chamber was maintained at 37°C and 5% CO2. Six to eight 
fields/well were imaged, with duplicate wells for each condition. 
3 μm ×  2 μm z-sections in the blue (40% power, 300  ms, 35% 
gain) and green (40% power, 300 ms, 35% gain) channels were 
captured in each field. The apoptotic fraction was calculated by 
dividing the number of cells fluorescing at 530 nm (corresponding 
to the cleaved caspase reporter reagent) by the number of nuclei 
(Hoechst staining). Image analysis was done using the CV7000 
image analysis software (Yokogawa Electric Corporation).
substrate Phosphorylation assay
Twelve thousand HeLa cells, 10,000 U2OS cells, or 8,000 RPE1 
cells were seeded into 96-well glass-bottom Sensoplates (Greiner) 
16 h before inhibitor addition. Prior to seeding, the glass-bottom 
plates were coated with poly-l-lysine (Sigma). All inhibitors were 
diluted in DMSO and added to cells in complete growth media 
(2× desired concentrations were prepared in complete growth 
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medium and added to wells). After 8  h cells were fixed with 
4% PFA for 20  min at room temperature. The fixed cells were 
washed with PBS. For immunostaining, cells were permeabilized 
and blocked with PBS containing 10% normal donkey serum 
(Jackson ImmunoResearch) and 0.1% Triton-X100 for 1  h at 
room temperature. Primary antibodies against phospho-LATS2 
(Ser 83), phospho-histone H3(Ser 28), and anti-phospho-MPM2 
(see Table S3 in Supplementary Material) were incubated for 1 h 
at room temperature. Cells were stained with Cy3-conjugated 
goat anti-rat, Alexa Fluor 488-conjugated goat anti-mouse IgG2b, 
and Alexa Fluor 647-conjugated goat anti-mouse IgG1 secondary 
antibodies (see Table S3 in Supplementary Material) and Hoechst 
33342 for 1 h at room temperature. Cells were then washed twice 
with PBS containing 0.1% Triton-X100. Image acquisition in four 
channels was performed using a CV7000 spinning disk confocal 
system (Yokogawa Electric Corporation) with a 40 ×  0.95 NA 
U-PlanApo objective and 2560  ×  2160 pixel sCMOS camera. 
Fluorophores (Hoechst 33342, Alexa Fluor 488, Cy3 and Alexa 
Fluor 647) were excited with 50% laser power for 300 ms and max-
imum projections of 8–14 μm × 1 μm z-sections were recorded. 
Fifty fields per well were imaged with quadruplicate wells for each 
condition. Image analysis was done using the CV7000 image anal-
ysis software (Yokogawa Electric Corporation). Between 100 and 
1,000 mitotic cells per condition were segmented applying object 
identification parameters to select for bright MPM2 labeling. 
Using a nuclear identifier protocol, minimum intensity thresholds 
were set for pLATS2(Ser 83) and the pH3(Ser 28) signals, and 
the resulting identified objects were eroded, dilated, and filtered 
for size by user-defined thresholds. For only the MPM2-positive 
mitotic cells, the mean fluorescence intensity of the identified 
pLATS2(Ser 83) and pH3(Ser 28) objects was measured, and the 
average intensity per cell per well was calculated. The same thresh-
olds were applied for all of the inhibitor-treated samples, which 
were processed, imaged, and analyzed in parallel with control 
DMSO-treated cells. Data were fit using a four-parameter, variable 
slope fit in Prism (GraphPad). Primary and secondary antibody 
dilutions can be found in Table S3 in Supplementary Material.
g2 Duration assay
HeLa, U2OS, and RPE1 cells co-expressing GFP-PCNA and 
H2B-RFP were seeded into 96-well glass bottom Sensoplates 
(Greiner) at 10,000 cells/well 16  h before inhibitor addition. 
Prior to seeding, glass-bottom plates were coated with poly-
l-lysine (Sigma). All inhibitors were diluted in DMSO and added 
to cells in complete growth media (2× desired concentrations 
were prepared in complete growth medium and added to wells). 
Movies were acquired on a CV1000 spinning disk confocal 
system (Yokogawa Electric Corporation) with a 20× U-PlanApo 
0.75 NA objective and 512 × 512 EM-CCD camera with 2 × 2 
binning. The humidity controlled imaging chamber was main-
tained at 37°C and 5% CO2. Three fields per well were imaged, 
with duplicate wells for each condition. 3 μm × 2 μm z-sections 
in the GFP (25% power, 100 ms, 20% gain) and RFP (20% power, 
100 ms, 20% gain) channels were captured in each field at 12-min 
intervals for 24 h. Cells were manually tracked from appearance 
of GFP-PCNA foci to the beginning of the next mitosis (NEBD). 
GFP-PCNA foci appear in the nucleus during mid to late S-phase, 
and the first frame in which these foci are no longer visible was 
defined as the beginning of G2 phase. Results represent combined 
measurements of 40-100 cells per condition from two independ-
ent experiments. Data were fit using a 4-parameter, variable slope 
fit in Prism (GraphPad).
cytokinesis assay
HeLa, U2OS, and RPE1 cells co-expressing YFP-α-tubulin and 
H2B-RFP were seeded into 96-well glass-bottom Sensoplates 
(Greiner) at 8,000 cells/well 16 h before inhibitor addition. Prior 
to seeding, glass-bottom plates were coated with poly-l-lysine 
(Sigma). All inhibitors were diluted in DMSO and added to cells 
in complete growth media (2× desired concentrations were pre-
pared in complete growth medium and added to wells). Movies 
were acquired on a CV1000 spinning disk confocal system 
(Yokogawa Electric Corporation) with a 40× U-PlanApo 0.95 
NA objective and 512 ×  512 EM-CCD camera. The humidity 
controlled imaging chamber was maintained at 37°C and 5% 
CO2. Eight fields per well were imaged, with duplicate wells for 
each condition. 5 μm × 2 μm z-sections in the YFP (25% power, 
100 ms, 20% gain) and RFP (20% power, 100 ms, 20% gain) chan-
nels were captured in each field at 5-min intervals for 24 h. Cells 
were manually tracked from mitosis to G1, and the appearance 
of microtubule midbodies and mono/binucleated daughter cells 
were analyzed to assess cytokinesis success. Results represent 
combined measurements of 50-100 cells per condition from two 
independent experiments. Data were fit using a 4-parameter, 
variable slope fit in Prism (GraphPad).
Western Blot analysis
For Aurora A inhibitors, HeLa cells were seeded into 10  cm 
dishes and treated with 100 nM taxol and DMSO or compounds 
in dose–response for 16 h. Cells were harvested at 50–80% con-
fluence and lysed in RIPA buffer supplemented with a protease/
phosphatase inhibitor cocktail (Thermo Fisher Scientific) using 
a Qsonica Q800R sonicator (10 min, 50% amplitude, 15 s on/15 s 
off). Before loading, concentrations of cleared extracts were 
normalized using a Bio-Rad Protein Assay (Bio-Rad). For every 
sample, 25–50 μg protein per lane was run on Mini-PROTEAN 
gels (Bio-Rad) and transferred to PVDF membranes using a 
TransBlot Turbo system (Bio-Rad). For primary anti-phospho-
Histone H3(Ser 10), anti-phospho-Histone H3(Ser 28), anti-
Aurora A, anti-Aurora B, anti-phospho-Aurora A(Thr 288)/
Aurora B(Thr 232)/Aurora C(Thr 198), anti-Histone H3, anti-
Cyclin B1, and anti-phospho-Aurora A (Thr 288) antibodies (see 
Table S3 in Supplementary Material), blocking and incubations 
were performed in TBS-Tween with 5% BSA or non-fat dry milk. 
Detection was performed using HRP-conjugated  secondary 
antibodies (see Table S3 in Supplementary Material), with 
SuperSignal West Femto (Thermo Fisher Scientific) substrates. 
Membranes were imaged on a ChemiDoc MP system (Bio-Rad).
Aurora B inhibitor analysis was done as described above with 
the following adaptations: seeded HeLa cells were synchronized 
using a 2.5 mM double-thymidine block. Eight hours after release, 
cells were treated with 10 μM MG132 and DMSO or compound 
in dose–response for 3  h. After PBS washing, treated cells were 
harvested with sample buffer, and the total cell lysate was heated 
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for 5 min at 95°C before sonication. Primary anti-phospho Histone 
H3(Ser 10), anti-phospho-Histone H3 (Ser 28), anti-Histone H3, 
anti-phospho-Aurora A(Thr 288)/Aurora B(Thr 232)/Aurora 
C(Thr 198), anti-Aurora B, and anti-Cyclin B1 antibodies were 
incubated and detected as described above. Primary and second-
ary antibody dilutions can be found in Table S3 in Supplementary 
Material.
aurora B Transcript Variant analysis
HeLa total cellular RNA was prepared using RNeasy (Qiagen) 
according to the manufacturer’s instructions. Random primer-
based cDNA synthesis was performed with MultiScribe reverse 
transcriptase (Applied Biosystems) from 500 ng RNA (20 μL reac-
tion volume, 10 min at 25°C, 120 min at 37°C, 5 min at 85°C). The 
cDNA was diluted 1:5, and 10 μl was used in a 50 μl PCR reaction 
with Q5 DNA polymerase (New England Biolabs) and the fol-
lowing primers: GGTCATTTGTAGCCACATCCTGTC (specific 
to human Aurora B transcript 5; nucleotides 108–131 of RefSeq 
NM_001313951) and GCATCTGCCAACTCCTCCATGATC 
(universal primer for human Aurora B transcripts; nucleotides 
687–664 of RefSeq NM_001313951). The PCR amplification 
conditions were (10 s at 98°C, 30 s at 69°C, 30 s at 72°C, 35 cycles). 
Reaction products were visualized by fluorescence on a 3% 
NuSieve GTG agarose gel. Identical PCR conditions were used 
for amplification with T7 and SP6 promoter sequences appended 
to the primers for direct sequencing after gel purification.
crystal structure of aurora a Bound to 
MK-5108
The kinase domain of human Aurora A (amino acids 123-390) 
was cloned into pET28a with an N-terminal 6XHis tag and an 
intervening rhinovirus 3C protease cleavage site. The protein 
was expressed in E. coli BL21 Rosetta 2(DE3) cells (Novagen) at 
16°C overnight. Cells were harvested by centrifugation, resus-
pended in a buffer containing 50  mM Tris (pH 8.0), 300  mM 
NaCl, 40 mM imidazole, 20 mM MgCl2, 10% glycerol, 0.5 mM 
TCEP, and an EDTA-free protease inhibitor cocktail, and lysed 
using a microfluidizer. After clarification via centrifugation, the 
lysate was loaded onto a HisTrap HP column (GE Healthcare), 
and the bound protein was eluted in a buffer containing 50 mM 
Tris (pH 8.0), 300 mM NaCl, 200 mM imidazole, 20 mM MgCl2, 
10% glycerol, and 0.5  mM TCEP. The tag was cleaved with 
Turbo3C protease (ETON) overnight at 4°C while being dialyzed 
against a buffer containing 20 mM Tris (pH 7.0), 200 mM NaCl, 
20 mM MgCl2, 10% glycerol, and 0.5 mM TCEP. Since both the 
6× His-tagged and untagged species bind metal affinity resins 
in this buffer, the cleavage reaction was loaded onto a HisTrap 
HP column and the untagged protein was selectively eluted in a 
buffer containing 20 mM Tris (pH 7.0), 200 mM NaCl, 40 mM 
imidazole, 20 mM MgCl2, 10% glycerol, and 0.5 mM TCEP. Trace 
amounts of the Turbo3C protease were removed using a GSTrap 
HP column (GE Healthcare). The untagged protein was further 
purified using size exclusion chromatography on a Superdex 
75 16/600 column (GE Healthcare). The final eluate [in 20 mM 
Tris (pH 7.0), 200 mM NaCl, 20 mM MgCl2, 10% glycerol, and 
0.5 mM TCEP] was concentrated to 6.2 mg/mL using Amicon 
Ultra 10K MWCO concentrators (Millipore), and MK-5108 was 
added from a 50  mM DMSO stock to a final concentration of 
500 μM.
The inhibitor bound protein was crystallized by hanging drop 
vapor diffusion using a reservoir buffer consisting of 100  mM 
BisTris (pH 6.5), 30% PEG3350 at 21°C. A total of 1.5 μL protein 
solution was mixed with 1.5 μL reservoir buffer and sealed in a 
chamber containing 400 μL of reservoir solution. After 1 week, a 
rod-shaped crystal (~100 μm × 5 μm × 5 μm) was transferred to 
a cryoprotectant containing 100 mM BisTris (pH 6.5), 200 mM 
NaCl, 20  mM MgCl2, 25% PEG3350, 10% glycerol, 30  μM 
MK-5108, and flash-frozen in liquid nitrogen.
X-ray diffraction data were measured using Beamline 7-1 at 
the Stanford Synchrotron Radiation Lightsource and processed 
with HKL2000 (115). The structure was determined by molecular 
replacement using PHASER (116) and sequential searches with 
the large and then the small lobes of an ensemble model (PDB: 
1MQ4, 2J4Z, 3FDN, 3LAU, 4UYN). Refinement was performed 
using PHENIX (117) interspersed with iterative cycles of 
rebuilding using Moloc (118). Figures were made using PyMol 
(Schrödinger).
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